Abstracts | 27 was taking 1.26 ± 0.51 types of ADs and the AAP augmentation group 1.31 ± 0.54, plus 1.06 ± 0.19 AAPs. At 2 weeks, response was observed in 11 patients (35.48%) in the AD group and 18 patients (35.29%) in the AAP augmentation group (χ 2 = 0, p = 1). At week 8, 16 (52.44%) and 27 patients (52.94%) achieved remission (χ 2 = 0, p = 1), respectively. However, baseline HDRS-17 total scores were 18.55 ± 5.73 and 22.39 ± 6.14 (t = 2.819, p < 0.01) for the AD and AAP groups, respectively. Conclusion: Compared with AD treatment, AAP augmentation did not show a more rapid response nor greater remission rates. Considering that the AAP augmentation group had more severe depressive symptoms at baseline, AAP augmentation may be effective in severe MDD.
Abstract
Sunshine increases placebo effect in major depressive disorder (MDD) patients (Gailledreau et al., 2015) . Kokras et al. (2014) showed that sunshine induces different responses in female than male mice in preclinical models of depression. Objective: To determine if the sunshine induced placebo effect exhibits gender differences in human Materiel and Methods: Data from 9 double-blind, randomized, placebo-controlled studies of antidepressants conducted by the French GICIPI network were reviewed. MADRS (5) or HAM-D 17 (4) were used as the main efficacy tool. For each patient, variation of scores (Delta MADRS/Delta HAM-D) between two consecutive visits were correlated with the average sunshine index observed at noon between these visits. Sunshine indexes were provided by Météo-France. Correlations were computed with Microsoft Excel. Results: Sunshine increases placebo effect: however analysis of both genders (n=52) demonstrates no statistically significant (NS) correlation (r 2 =0.0064). Analysis of the males (n=8) demonstrates NS correlation in cloudy (< 1000 Joules/cm Although analysis of the females (n=44) demonstrates NS correlation as well for cloudy or variable weather (r 2 =0.0016), there is a strong correlation between sunshine index and Delta MADRS/ Delta HAMD for females exposed to sunny weather: r 2 =0,315, n=20, p<0.01. This correlation is even stronger in the subpopulation of females aged less than 50 years: r 2 =0.6398, n=12, p<0.001. Discussion: The hypothesis underlying this correlation between sunshine index and variations of MADRS/HAMD scales will be discussed. Conclusion: Sunshine increases placebo effect in female patients aged less than 50. This insufficiently known effect may be responsible for failure of a number of double-blind, randomized, studies of antidepressant compounds.
PS80
Utilization Global Impression Improvement (CGI-I), Working-LimitationQuestionnaire (WLQ), the patient-reported Perceived Deficits Questionnaire (PDQ), the Working Limitation Questionnaire (WLQ), MADRS, and UPSA. Construct validity was examined via baseline correlation analyses of the UPSA Composite Score ("UPSA," comprising the UPSA and UPSA-B in English-and nonEnglish-speaking patients, respectively) and clinical outcomes. Anchor-based (CGI-I ≤2) and distribution-based (one-half SD) analysis methods were used to establish a responder definition. Results: Mean UPSA score at baseline was 77.8 (SD=12.88). Significant baseline correlations (p<0.05) were observed between the UPSA and duration of current major depressive episode (MDE) (r=0.10), age (r=-0.13), education (r=0.29), DSST (r=0.36), and WLQ (r=-0.17), but not MADRS or PDQ. MADRS was only correlated (p<0.05) with duration of the current MDE (r=0.13) and the PDQ (r=0.32). The anchor-based approach resulted in an estimate of a 6.7-point improvement for a responder definition on the UPSA, which was supported by the distribution-based approach (one-half SD = +6.44).
Conclusion:
The UPSA was correlated with cognitive performance (DSST) and workplace productivity (WLQ) but not mood (MADRS) or subjective cognitive functioning (PDQ), supporting the construct validity of the UPSA for functional capacity in patients with MDD independent of mood symptoms. Anchor-based and distributional analyses suggest a ~7-point improvement in UPSA as a responder definition for treatment response. 
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Abstract Background: The possible dose-dependency for the antidepressant effect of selective serotonin reuptake inhibitors (SSRIs) remains controversial. We have conducted the first comprehensive patient level mega-analysis exploring this issue, one incentive being to address the possibility that inclusion of low-dose arms in previous meta-analyses may have caused an underestimation of the efficacy of these drugs.
